Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2019-002423-15 | EudraCT Number |
Not provided
Not provided
Delays due to COVID
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Helse Stavanger HF | OTHER_GOV |
| Michael J. Fox Foundation for Parkinson's Research | OTHER |
| Parkinson's UK | OTHER |
| AstraZeneca |
Not provided
Not provided
Not provided
Not provided
To test for the first time the potential of a nicotinic agonist on cognitive symptoms in people with mild cognitive impairment (MCI) in Parkinson's disease (PD), referred to as PD-MCI.
There is an unmet clinical need to treat PD-MCI. As outlined previously, PD-MCI is common, has important clinical consequences, and there is currently no available treatment. Moreover, the underlying pathology of cognitive impairment in PD indicates that nicotinic agonists may be particularly relevant for this condition. This is a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study of AZD0328, a selective α7 nicotinic receptor agonist, in PD-MCI. The study is an international, multi-centre study, which will take place across sites in Europe.
PD-MIND will for the first time test the potential of a nicotinic agonist on cognition in PD-MCI. The primary outcome is attention, as it is a key cognitive domain in the PD-MCI profile and most likely to be affected by a α7 nicotinic agonist. Exploratory outcome measures will guide decisions on the design and conduct of future larger Phase 3 trials. Qualifying participants will be randomly assigned at baseline to either receive 0.5mg twice a day (bis in die, BID) of AZD0328 or placebo for 12 weeks. A total of 160 participants with PD-MCI will be enrolled to the study: 80 in the active (AZD0328) group and 80 in the control (placebo) group. Participants will undertake face-to-face assessments at screening, baseline, and then 3- 6- and 12- weeks after beginning study treatment (see Figure 2 for trial design overview). A subset of 90 participants will also undergo an MRI biomarker component prior to study drug administration and at study end.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active drug: AZD0328 | Experimental | Participants will receive AZD0328 capsules for oral administration.AZD0328 is a selective α7 nicotinic receptor agonist, The total daily dosage of AZD0328 is 1mg per day; administered as 0.5mg twice daily / BID. The study treatment period is 12-weeks. |
|
| Placebo | Placebo Comparator | Participants will receive identical-appearing placebo capsules for oral administration.Participants will be instructed to take 2 capsules in the morning and 2 capsules in the evening for a 12-week period. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD0328 | Drug | Active study drug |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Attentional Intensity Index composite factor score from baseline to week 12 | The Attentional Intensity Index composite factor score combines the speed scores from the three attention tasks (simple reaction time, choice reaction time and digit vigilance), and has been validated using factor analysis. The measure reflects the ability to focus attention and process information. | From baseline to week 12 (end of treatment period). |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Attentional Intensity Index composite factor score from baseline to week 6 | The Attentional Intensity Index composite factor score combines the speed scores from the three attention tasks (simple reaction time, choice reaction time and digit vigilance), and has been validated using factor analysis. The measure reflects the ability to focus attention and process information. | From baseline to week 6 (mid-point of treatment period) |
| Measure | Description | Time Frame |
|---|---|---|
| Screening/Baseline whole-brain and regionally specific brain volumes as predictors of treatment response | MRI scans | At screening/baseline (pre-medication dosing) |
| Screening/Baseline whole-brain perfusion as well as perfusion in ROIs as predictors of treatment response |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dag Aarsland, PhD | King's College London; Stavager Univeristy Hospital | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| D060825 | Cognitive Dysfunction |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C543642 | spiro(1-azabicyclo(2.2.2)octane-3,2'(3H)-furo(2,3-b)pyridine) |
Not provided
Not provided
Not provided
| INDUSTRY |
| Masaryk University | OTHER |
| Norges Parkinsonforbund, Norway | UNKNOWN |
| University of Exeter | OTHER |
| Stichting Lygature | UNKNOWN |
| Innovative Medicines Initiative | OTHER |
This is a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study of AZD0328, a selective α7 nicotinic receptor agonist, in PD-MCI.
Not provided
Not provided
Not provided
| Drug |
Non-active study drug |
|
| Change in Sustained Attention Index composite factor score from baseline to week 6 and week 12 | The Sustained Attention Index composite factor score combines the accuracy scores from choice reaction time and digit vigilance tasks, and reflects the ability to sustain attention and ignore distraction. | From baseline to week 6 (mid-point of treatment period) and week 12 (end of treatment period) |
| Change in Working Memory Index composite factor score from baseline to week 6 and week 12 | The Working Memory Index composite factor score combines the accuracy scores from the two working memory tasks to form this measure, which reflects the capability of holding information in working memory. | From baseline to week 6 (mid-point of treatment period) and week 12 (end of treatment period) |
| Change in Episodic Memory Index composite factor score from baseline to week 6 and week 12 | The Episodic Memory Index composite factor score combines the verbal recall and recognition tasks with visual recognition. It reflects the longer term memory capability, like how well someone can remember a short story or what they had for dinner last night, or what they did on their last birthday. | From baseline to week 6 (mid-point of treatment period) and week 12 (end of treatment period) |
| Change in Memory Speed Retrieval Index composite factor score from baseline to week 6 and week 12 | The Memory Speed Retrieval Index composite factor score combines the speed scores from the two working memory tasks and the picture recognition task. Factor analysis has established that the speed of retrieval from working memory and episodic memory load on a common factor, and the score reflects the time taken to successfully retrieve information held in memory. | Fom baseline to week 6 (mid-point of treatment period) and week 12 (end of treatment period) |
| Change in MoCA score from screening to week 12 | The Montreal Cognitive Assessment (MoCA) assesses 8 cognitive areas: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall, and orientation. Scores range from 0 to 30, with lower scores indicative of greater cognitive impairment. | From screening to week 12 (end of treatment period) |
| Change in Sustained Attention Index composite factor score from week 12 to week 16 | The Sustained Attention Index composite factor score combines the accuracy scores from choice reaction time and digit vigilance tasks, and reflects the ability to sustain attention and ignore distraction. | From week 12 (end of treatment period) to week 16 (4 weeks after end of study medication dosing) |
| Change in Working Memory Index composite factor score from week 12 to week 16 | The Working Memory Index composite factor score combines the accuracy scores from the two working memory tasks to form this measure, which reflects the capability of holding information in working memory. | From week 12 (end of treatment period) to week 16 (4 weeks after end of study medication dosing) |
| Change in Episodic Memory Index composite factor score from week 12 to week 16 | The Episodic Memory Index composite factor score combines the verbal recall and recognition tasks with visual recognition. It reflects the longer term memory capability, like how well someone can remember a short story or what they had for dinner last night, or what they did on their last birthday. | From week 12 (end of treatment period) to week 16 (4 weeks after end of study medication dosing) |
| Change in Memory Speed Retrieval Index composite factor score from week 12 to week 16 | The Memory Speed Retrieval Index composite factor score combines the speed scores from the two working memory tasks and the picture recognition task. Factor analysis has established that the speed of retrieval from working memory and episodic memory load on a common factor, and the score reflects the time taken to successfully retrieve information held in memory. | From week 12 (end of treatment period) to week 16 (4 weeks after end of study medication dosing) |
| Change in MDS-UPDRS Part III motor examination subscale score from baseline to week 12 | Part III of the Movement Disorder Society's (MDS) Unified Parkinson's Disease Rating Scale (UPDRS), is a motor examination and objective assessment of parkinsonism. This is based on 18 items assessed by the investigator, resulting in 33 scores by location and lateralization. These 33 scores are ratings on severity: from 0 (normal) to 4 (severe).The MDS-UPDRS-III total score ranges from 0 to 132, with higher scores indicative of more severe motor and functional impairment. | From baseline to week 12 (end of treatment period) |
| Change in total score from the Non-Motor Symptom Scale from baseline to week 12 | The Non-Motor Symptoms Scale (NMSS) is a 30-item rater-based scale to assess a wide array of non-motor symptoms in patients with Parkinson's disease. The NMSS measures severity (scored 0 - 3) and frequency (scored 1 - 4) of non-motor symptoms across nine dimensions. The NMSS total score ranges from 0 to 360, with higher score indicative of worse non-motor symptoms. | From baseline to week 12 (end of treatment period) |
| Change in total score from the 39-item Parkinson's Disease Questionnaire from baseline to week 12 | The 39-item Parkinson's Disease Questionnaire (PDQ-39) is a health-related quality-of-life questionnaire. The questionnaire contains 39 self-reported items on eight domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and body discomfort. Each item is scored on 5-point Likert-type scale from 0 (never) - 4 (always), over the past month. The PDQ-39 total score is 156: the lower the score reflects a better health-related quality-of-life. | From baseline to week 12 (end of treatment period) |
| Change in MCI-CGIC from baseline to week 12 | The MCI-adjusted Clinical Global Impression of Change (CGIC) score is generated in the context of a semi-structured interview and is an indication of the change in the participant's global status, cognition, behaviour, and functional abilities on a 7-point scale, with the best score being 'marked improvement' and the worst being 'marked worsening.' | From baseline to week 12 (end of treatment period) |
| Change in depression and anxiety subscale scores from the HADS from baseline to week 12 | The Hospital Anxiety and Depression Scale (HADS), has an anxiety (score 0 - 21) and a depression subscale (0 - 21), with higher subscales scores indicative of greater levels of depression / anxiety | From baseline to week 12 (end of treatment period) |
| Incidence, nature and severity of AEs and SAEs during treatment period | Adverse Events (AEs) and Serious Adverse Events (SAEs) | From baseline to week 12 (end of study treatment) |
| Incidence of dosage reduction or treatment discontinuation during treatment period | Dosage reduction or treatment discontinuation | From baseline to week 12 (end of study treatment) |
| Incidence of clinically significant changes or abnormal electrocardiogram (ECG) assessments, vital sign measurements and clinical laboratory values during treatment period | Clinically significant laboratory values or vital sign measurements | From baseline to week 12 (end of study treatment) |
| Changes in whole-brain and regionally specific brain volumes from baseline/screening to week 12 | MRI scans | From screening/baseline (pre-medication dosing) to week 12 (end of study treatment) |
| Changes in whole-brain perfusion as well as perfusion in regions of interests (ROIs) from baseline/screening to week 12 | MRI scans | From screening/baseline (pre-medication dosing) to week 12 (end of study treatment) |
| Changes in functional resting-state connectivity of the large-scale cognitive brain networks from baseline/screening to week 12 | MRI scans | From screening/baseline (pre-medication dosing) to week 12 (end of study treatment) |
MRI scans |
| At screening/baseline (pre-medication dosing) |
| Screening/Baseline functional resting-state connectivity of the large-scale cognitive brain networks as predictors of treatment response | MRI scans | At screening/baseline (pre-medication dosing) |
| Placebo-controlled change in levels of exploratory blood-based biomarkers for neuroprotection and/or disease modification changes | Blood-based biomarkers (e.g. cytokines, amyloid species, tau and alpha-synuclein) | At baseline and week 12 |
| Change in levels of study medication in blood from baseline to week 12 | Levels of study medication in blood | From baseline to week 12 (end of treatment period) |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |